Submission of Matters to a Vote of Security Holders
Show detailsHide details
5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Palatin Technologies, Inc.
A biopharmaceutical company that develops medicines working on the body's melanocortin receptor system, Palatin Technologies is headquartered in Princeton, New Jersey. Its most visible product is Vyleesi, an FDA-approved injectable treatment for low sexual desire in premenopausal women, delivered through a self-administered autoinjector. Founded in 1986 by Carl Spana and John K.A. Prendergast, the company also develops treatments for obesity and rare metabolic disorders.
5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events
1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
3.03 Material Modification to Rights of Security Holders · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits